Skip to Main Content

Author Details

Timothy A Chan
Cleveland Clinic.
1994
230
96
PMIDPaper TitleJournal TitlePublished Year
37333401Neutrophil to Lymphocyte Ratio (NTLR) Predicts Local Control Failure and Overall Survival after Stereotactic Body Radiotherapy (SBRT) In Metastatic Sarcoma.Res Sq2023
37561583Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma.J Clin Invest2023
37626188Author Correction: 14-3-3Ï¿ is required to prevent mitotic catastrophe after DNA damage.Nature2023
37333401Neutrophil to Lymphocyte Ratio (NTLR) Predicts Local Control Failure and Overall Survival after Stereotactic Body Radiotherapy (SBRT) In Metastatic Sarcoma.Res Sq2023
37529400Characterizing the Immune Microenvironment and Neoantigen Landscape of Hürthle Cell Carcinoma to Identify Potential Immunologic Vulnerabilities.Cancer Res Commun2023
37529400Characterizing the Immune Microenvironment and Neoantigen Landscape of Hürthle Cell Carcinoma to Identify Potential Immunologic Vulnerabilities.Cancer Res Commun2023
37561583Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma.J Clin Invest2023
37626188Author Correction: 14-3-3Ï¿ is required to prevent mitotic catastrophe after DNA damage.Nature2023
34635506Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy.Mol Cancer Res2022
36044718Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function.JCO Precis Oncol2022
35705800Author Correction: Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies.Nat Immunol2022
35704596Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.Sci Transl Med2022
36288724Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer.Immunity2022
35817971Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity.Nat Genet2022
35618834Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies.Nat Immunol2022
36323682FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation.Nat Commun2022
36252564Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma.J Immunother Cancer2022
35398668Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cells.Neoplasia2022
36564410Author Correction: FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation.Nat Commun2022
36536472Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape.Genome Med2022
34987156Author Correction: Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling.Nat Commun2022
34725502Improved prediction of immune checkpoint blockade efficacy across multiple cancer types.Nat Biotechnol2022
34635506Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy.Mol Cancer Res2022
35705800Author Correction: Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies.Nat Immunol2022
35704596Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.Sci Transl Med2022
35398668Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cells.Neoplasia2022
35817971Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity.Nat Genet2022
35618834Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies.Nat Immunol2022
36536472Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape.Genome Med2022
36564410Author Correction: FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation.Nat Commun2022
36044718Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function.JCO Precis Oncol2022
36323682FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation.Nat Commun2022
36288724Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer.Immunity2022
36252564Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma.J Immunother Cancer2022
34987156Author Correction: Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling.Nat Commun2022
34725502Improved prediction of immune checkpoint blockade efficacy across multiple cancer types.Nat Biotechnol2022
32726432Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy.J Natl Cancer Inst2021
31813809Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course.Eur Urol Focus2021
33861994Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy.Cancer Cell2021
33526794Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors.Nat Commun2021
33674442Qa-1<sup>b</sup> Modulates Resistance to Anti-PD-1 Immune Checkpoint Blockade in Tumors with Defects in Antigen Processing.Mol Cancer Res2021
33834176Mutations in <i>BRCA1</i> and <i>BRCA2</i> differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy.Nat Cancer2021
33727676Immunotherapy biomarkers: the long and winding road.Nat Rev Clin Oncol2021
34261695Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma.Clin Cancer Res2021
34039647High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.Mol Cancer Res2021
33599686Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.JAMA Oncol2021
34316321Resource-efficient pooled sequencing expands translational impact in solid tumors.Kidney Cancer J2021
34354864Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer.Am J Cancer Res2021
32726432Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy.J Natl Cancer Inst2021
33429428Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial.J Natl Cancer Inst2021
  • 1 - 50 of 460

Recommended Authors

Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 8
Zachary L Skidmore
Washington University in St. Louis School of Medicine
Career Start Year 2015
Number of shared co-authors 5
Huwate Yeerna
Moores Cancer Center, University of California
Career Start Year 2015
Number of shared co-authors 3
Katie M Campbell
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 2014
Number of shared co-authors 8
Michael Bockmayr
Institute of Pathology, Charite Universitatsmedizin Berlin
Career Start Year 2013
Number of shared co-authors 4
Arshi Arora
Memorial Sloan Kettering Cancer Center
Career Start Year 2011
Number of shared co-authors 19
Francesco Favero
Universita del Piemonte Orientale
Career Start Year 2010
Number of shared co-authors 5
Ganiraju C Manyam
the University of Texas MD Anderson Cancer Center
Career Start Year 2009
Number of shared co-authors 27
Oscar Krijgsman
The Netherlands Cancer Institute
Career Start Year 2008
Number of shared co-authors 2
David A Quigley
University of California-San Francisco
Career Start Year 2008
Number of shared co-authors 6
Lawrence N Kwong
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 35
Ritu Roy
University of California San Francisco.
Career Start Year 2007
Number of shared co-authors 6
Linghua Wang
The University of Texas M. D. Anderson
Career Start Year 2006
Number of shared co-authors 36
Trevor J Pugh
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2003
Number of shared co-authors 41
Elena Ivanova
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 33
Lixia Diao
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 33
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 9
Olivier Elemento
Meyer Cancer Center
Career Start Year 2002
Number of shared co-authors 61
Michael Slifker
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 1
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 3
Li Ding
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 1997
Number of shared co-authors 77
Anthony J Iafrate
Massachusetts General Hospital
Career Start Year 1997
Number of shared co-authors 32
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 22
Peter S Hammerman
Novartis Institutes for BioMedical Research
Career Start Year 1996
Number of shared co-authors 49
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 4
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Career Start Year 1996
Number of shared co-authors 11
Curtis Gumbs
The University of Texas MD Anderson Cancer Center
Career Start Year 1995
Number of shared co-authors 9
Woong-Yang Park
Samsung Genome Institute, Samsung Medical Center
Career Start Year 1995
Number of shared co-authors 28
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 44
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 33

Collaborators

Luc G T Morris
Memorial Sloan Kettering Cancer Center
Co-authored papers 53
Vladimir Makarov
Center for Immunotherapy and Precision-Immuno-Oncology, Cleveland Clinic
Co-authored papers 42
Nadeem Riaz
Memorial Sloan Kettering Cancer Center
Co-authored papers 35
Fengshen Kuo
Memorial Sloan Kettering Cancer Center
Co-authored papers 32
Abraham Ari Hakimi
Co-authored papers 26
Jason T Huse
Co-authored papers 19
Cameron Brennan
Co-authored papers 16
Michael F Berger
Co-authored papers 14
Victor E Reuter
Memorial Sloan Kettering Cancer Center
Co-authored papers 11
Agnes Viale
Memorial Sloan Kettering Cancer Center
Co-authored papers 11
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Co-authored papers 10
Stephen B Baylin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Co-authored papers 10
Alan L Ho
Memorial Sloan Kettering Cancer Center
Co-authored papers 10
Nora Katabi
Memorial Sloan Kettering Cancer Center
Co-authored papers 9
Bert Vogelstein
Co-authored papers 9
Kenneth W Kinzler
Co-authored papers 9
Jorge S Reis-Filho
Memorial Sloan-Kettering Cancer Center
Co-authored papers 8
Richard J Wong
Memorial Sloan Kettering Cancer Center
Co-authored papers 8
Barry S Taylor
Memorial Sloan Kettering Cancer Center
Co-authored papers 8
Chris Sander
Broad Institute of MIT and Harvard
Co-authored papers 8
William Lee
Co-authored papers 8
Zhigang Zhang
Memorial Sloan Kettering Cancer Center
Co-authored papers 8
Mark Lee
Memorial Sloan Kettering Cancer Center (MSKCC)
Co-authored papers 8
Nancy Y Lee
Memorial Sloan Kettering Cancer Center
Co-authored papers 7
Marc Ladanyi
Memorial Sloan Kettering Cancer Center
Co-authored papers 7
Thomas J Kaley
Memorial Sloan Kettering Cancer Center
Co-authored papers 7
Xin Pei
Memorial Sloan Kettering Cancer Center
Co-authored papers 7
Niels Weinhold
Co-authored papers 7
James J Hsieh
Washington University
Co-authored papers 6
Yasin Senbabaoglu
Co-authored papers 6
Release 1.2